Sign in Subscribe
Biological markers

Long-term Effects of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in People with HIV and HBV Coinfection

Strategic Insights

— 1 min read

Research conducted by investigators at the University of Bari Aldo Moro in Italy has shed light on the long-term effects of switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on hepatic, renal, and metabolic parameters in people with HIV (PWH) and HBV coinfection. The study, published in the International Journal of Infectious Diseases, analyzed data from the ICONA cohort, excluding those who started antiviral treatment or had detectable HCV-RNA during the study period.

Key Takeaways:

  • The study found that switching from TDF to TAF led to a modest decrease in Alanine Aminotransferase (ALT) levels in participants with chronic liver enzyme elevation, with reductions of up to -22.6 U/L at 24 months post-switch.
  • Total cholesterol, LDL-Cholesterol, and triglycerides increased by 14.46, 10.70, and 11.56 mg/dL at 6 months post-switch, respectively, and then stabilized thereafter.
  • PWH with baseline LDL-Cholesterol levels above 100 mg/dL showed a significant increase in LDL-Cholesterol levels after the switch.
  • Greater hepatic improvement was noticed after TDF to TAF switch in PWH with HBV coinfection, with no differences in lipid increases compared to monoinfected patients.
  • The study's findings provide valuable insights into the long-term effects of switching from TDF to TAF in ART-experienced PWH with and without hepatic coinfection.

Statistics:

  • -3.05 [-6.42, 0.31] U/L decrease in ALT levels at 6 months post-switch.
  • 14.46 mg/dL increase in total cholesterol levels at 6 months post-switch.
  • 10.70 mg/dL increase in LDL-Cholesterol levels at 6 months post-switch.
  • 11.56 mg/dL increase in triglycerides levels at 6 months post-switch.
  • -20.5 to -22.6 U/L decrease in ALT levels in participants with chronic liver enzyme elevation at 24 months post-switch.

Sources:

  • NewsRx. Data on Biomarkers Described by Researchers at University of Bari Aldo Moro (Long-term trajectories of Hepatic and Metabolic biomarkers after switching from TDF to TAF in ART-Experienced PWH with and without Hepatic Coinfection: Data from the ...). AIDS Weekly. October 20, 2025; p 45.
  • International Journal of Infectious Diseases. Long-term trajectories of Hepatic and Metabolic biomarkers after switching from TDF to TAF in ART-Experienced PWH with and without Hepatic Coinfection: Data from the ICONA Cohort. 2025:108081.

Read more